This peer-reviewed article from interdisciplinary experts describes the impact of the IMbrave150 trial on treating advanced hepatocellular carcinoma.


The HCC Experts Round Table (Americas & Europe) brought together international experts in hepatocellular carcinoma, from fields including oncology, hepatology, radiology, patient advocacy, and health economics. The HCC Experts Round Table has recently published their assessment of the impact of the IMbrave150 trial on standards of care for advanced first-line HCC.

Watch the video overview from manuscript senior author Prof. Peter Galle and download your educational slides, summarizing the conclusions of the HCC Experts Round Table in their peer-reviewed publication. This educational content is relevant for all clinical team members involved in the care of advanced HCC.

Kulik L, da Fonseca LG, He AR, Rimola J, Wilson Woods A, Zöllner YF, Galle PR. Potential Impact of IMbrave150 Results in the Evolving Treatment Landscape of Advanced Hepatocellular Carcinoma: A Multidisciplinary Expert Opinion. J Hepatocell Carcinoma. 2020;7:423

This programme is supported by an Independent Educational Grant from Roche.

Hello, my name is Peter Galle, from the University Medical Center in Mainz, Germany. Last year, a multidisciplinary team of experts convened to discuss the impact of the IMbrave150 trial, assessing the combination of atezolizumab and bevacizumab in hepatocellular carcinoma.

This resulted in a position paper, where we discuss the important aspects of the trial with respect to efficacy, safety, and the impact on scheduling of systemic therapy in hepatocellular carcinoma.

We are now at a situation where we have seen a timely update of the data from 2020, which appeared at the ASCO GI meeting in January 2021 in San Francisco. It was good to see that the improvement of overall survival (OS) was not only confirmed, but now it was actually given in absolute numbers: we see a six-month improvement in overall survival comparing atezo + bev versus sorafenib.

This has resulted in the meantime in the approval of this combination in more than 160 countries worldwide, for the benefit of our patients. Thank you for your interest.

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Roche
I agree that this educational programme:

Was valuable to me

1/4

Other programmes of interest

Other
Oncology 
The evolving role of liquid biopsy in biomarker testing

Clinical application of liquid biopsy, and how it applies to NSCLC, breast and colorectal cancer

Experts
Assoc. Prof. Umberto Malapelle
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jul 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Interactive patient case
Oncology 
Advanced renal cell carcinoma: Managing a long-term durable response

Maximising outcomes for patients with advanced RCC 

Experts
Prof. Michael Staehler
Endorsed by
Urobel VZW | ASBL
  • clock 15 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Eisai Europe Limited.
Other

Episode

1

of 1

episode
Oncology 
Overcoming pre-analytical phase challenges in gastric, prostate and lung cancer

Medical experts make recommendations for best practice

Experts
Dr Alexander Wyatt, Prof. Frédéric Bibeau
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.
Conference update
Oncology 
Oncogene-addicted NSCLC: Highlights from ASCO 2024

The latest non-small cell lung cancer data presented at ASCO

Experts
Prof. Nicolas Girard
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Upper lower GI cancer update ASCO 2024 Conference update
Oncology 
Upper and lower GI cancer update from ASCO 2024

GI oncologists review the latest data presented at ASCO 2024

Experts
Dr Samuel J Klempner, Dr Elizabeth Smyth, Prof. Jenny Seligmann, Dr Dominik Modest
  • clock 8 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Experts Knowledge Share Video
Oncology Hemato-oncology 
Optimising the management of multiple myeloma in the early relapsed/refractory setting (RRMM)

Medical experts discuss the latest learnings from clinical practice

Experts
Prof. Aurore Perrot, Prof. Hermann Einsele, Assoc. Prof. Karthik Ramasamy, Assoc. Prof. Joshua Richter
  • download Downloadable
    Resources
  • clock 76 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline Oncology.